Probiotics for Parkinson’s Disease

  title={Probiotics for Parkinson’s Disease},
  author={Parisa Gazerani},
  journal={International Journal of Molecular Sciences},
  • P. Gazerani
  • Published 23 August 2019
  • Biology, Psychology
  • International Journal of Molecular Sciences
Parkinson’s disease (PD) is a complex neurological disorder classically characterized by impairments in motor system function associated with loss of dopaminergic neurons in the substantia nigra. After almost 200 years since the first description of PD by James Parkinson, unraveling the complexity of PD continues to evolve. It is now recognized that an interplay between genetic and environmental factors influences a diverse range of cellular processes, reflecting on other clinical features… 

Figures and Tables from this paper

The Role of Probiotics in Parkinson's Disease: A Review Study
An upward trend in the incidence of Parkinson’s disease (PD), known as one of the most prominent neurodegenerative maladies, has evoked great concerns among medical community over the past decades.
New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota
This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotic; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
Gut brain axis: an insight into microbiota role in Parkinson's disease.
Investigations that have been done to explore the gastrointestinal involvement in Parkinson's disease, the effect of dysbiosis, and potential therapeutic strategies for PD are discussed.
Association of Parkinson’s Disease With Microbes and Microbiological Therapy
This review expounded the mechanism of action between intestinal flora and PD as well as the transmission mode of α - synuclein in neurons, and found some potential values in improving the constipation of PD patients, promoting the growth of probiotics, and improving the level of intestinal inflammation.
Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson’s Disease
Results showed that long-term administration of probiotics has neuroprotective effects on dopamine neurons and further attenuates the deterioration of motor dysfunctions in MitoPark PD mice, highlighting the promising possibility of the potential use of probiotic treatment on human PD subjects.
The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson’s disease?
Preclinical and clinical investigations discussed in this review strengthen the correlation between intestinal microbiota and brain and the concept that modifying the microbiome composition may improve brain neurochemistry, modulating different pathways, confirming that gut microbiota modulation influences different pro- survival pathways.
Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models
The findings indicate that this probiotic formulation can counteract the detrimental effect of 6-OHDA in vitro and in vivo models of PD, and suggest that SLAB51 can be a promising candidate for the prevention or as coadjuvant treatment of PD.
The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review
The role of α-synuclein in non-motor disease pathology, proposed pathways constituting the connection between the gut microbiome and the brain, existing evidence related to pre- and probiotic interventions, and the potential opportunity for the development of novel preventative measures and therapeutic options that could target the microbiome–gut–brain axis in the context of Parkinson’s disease are discussed.


Gut dysfunction in Parkinson's disease.
The extensive involvement of the gut in PD even in its early stages has led to the evaluation of enteric α-synuclein as a possible biomarker of early PD, and one important aspect of gut dysfunction is its contribution to the clinical fluctuations in PD.
Gut microbiota are related to Parkinson's disease and clinical phenotype
The findings suggest that the intestinal microbiome is altered in PD and is related to motor phenotype, and the suitability of the microbiome as a biomarker is warranted.
Parkinson’s Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation
The restoration of the gut microbiome in patients with PD may alter the clinical progression of PD and this alteration can be accomplished by carefully designed studies using customized probiotics and fecal microbiota transplantation.
The gut‐brain axis in Parkinson's disease: Possibilities for food‐based therapies
The Gut and Parkinson’s Disease: Hype or Hope?
This mini-review attempts to concisely summarize the current knowledge after two decades of research on the gut-brain axis in PD, focusing on alpha-synuclein pathology, biomarkers, and the gut microbiota and envision the development and impact of these research areas for the two decades to come.
Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease
Therapeutic intervention through whole foods, dietary patterns, and supplemental nutrition (probiotics, prebiotic, and synbiotics) may positively impact intestinal milieu and result in reduced inflammation and oxidation and reduced risk for PD.
Brain-gut-microbiota axis in Parkinson's disease.
A better understanding of the brain-gut-microbiota axis interactions should bring a new insight in the pathophysiology of PD and permit an earlier diagnosis with a focus on peripheral biomarkers within the enteric nervous system.
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Clinical and pathological evidence is presented to support the hypothesis that PD starts in the gut and spreads via trans-synaptic cell-to-cell transfer of pathology through the sympathetic and parasympathetic nervous systems to the substantia nigra and the CNS.
Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence
Background: Parkinson's disease (PD) is characterized by loss of dopaminergic neurons and intraneuronal accumulation of alpha-synuclein, both in the basal ganglia and in peripheral sites, such as the
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
A better understanding of the dialogue sustained by the microbiota-gut-brain axis and innate immunity via TLR signaling should bring interesting insights in the pathophysiology of PD and provide novel dietary and/or therapeutic measures aimed at shaping the gut microbiota composition, improving the intestinal epithelial barrier function and balancing the innate immune response in PD patients.